Health Care · Services-Commercial Physical & Biological Research · OTC · CIK 1812360 · FYE Dec 31 · Prices AT CLOSE 2026-07-13 (USD) — end-of-day, never a live or intraday quote · STALE: the feed has not advanced this name
Last $0.11Day +0.00%1Y −61.8%Off 52W high −68.6%Vol (1Y) 359291.6%
Daily closing price, split-adjusted to the current basis; 2.9y shown of 945 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest0.0% of sh out |
| Days to cover1.0d |
| Next report (est.)2026-08-14 |
Short interest is FINRA semi-monthly, settlement 2026-06-30.
| Sales (TTM)$18.4M |
| Earnings (TTM)-$13.3M |
| ROE−151.0% |
| Net margin−75.9% |
| ROIC−101.5% |
| Sales growth 3Y217.6% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+109900.0% |
| 1Y−61.8% |
| 3Y−99.7% |
| Since incept. (ann.)−90.2% |
Total return through 2026-07-13 · series begins 2022-09-16. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)359291.6% |
| Ann. volatility (3Y)204187.6% |
| Sharpe (1Y)1.03 |
| Sharpe (3Y)0.58 |
| Max drawdown (1Y)−100.0% |
| Max drawdown (3Y)−100.0% |
| Beta (3Y vs SPY)−268.20 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
No 13F holders on file for FOXO.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | — | — | $5.2M | +63.0% |
| 2025-12-31 | 2026-04-15 | — | — | $4.4M | +57.1% |
| 2025-09-30 | 2025-11-10 | — | — | $3.5M | +196.5% |
| 2025-06-30 | 2025-08-19 | — | — | $5.2M | +18893.9% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-14 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Health Cares 98% · Life Science Services 2% · Corporate And Other 0% · Labs 0%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
